{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:59:56Z","timestamp":1781175596347,"version":"3.54.1"},"reference-count":42,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: retreatment with radionuclide-labeled somatostatin analogues following disease progression after initial treatment cycles is often referred to as salvage peptide receptor radionuclide therapy (salvage PRRT). Salvage PRRT is shown to have a favorable safety profile in patients with metastatic neuroendocrine tumors (NETs), but numerous questions about the efficacy and prognostic or predictive factors remain to be answered. The purpose of this study was to evaluate two parameters that have shown prognostic significance in progression-free survival (PFS) in initial PRRT treatment, namely the size of the largest lesion (LLS) and the De Ritis ratio (aspartate aminotransferase (AST)\/alanine aminotransferase (ALT)), as prognostic factors in the context of salvage PRRT. In addition, the PFS after initial PRRT was evaluated as a predictor of the PFS following salvage PRRT. (2) Methods: retrospective, monocentric analysis in 32 patients with NETs (gastroenteropancreatic, 23; unknown primary, 7; kidney, 1; lung, 1) and progression after initial PRRT undergoing retreatment with [177Lu]Lu-DOTATOC. The prognostic values of LLS, the De Ritis ratio, and PFS after initial treatment cycles regarding PFS following salvage PRRT were evaluated with univariable and multivariable Cox regression. PFS was defined as the time from treatment start until tumor progression according to RECIST 1.1 criteria, death from any cause or start of a new treatment due to progression of cancer-related symptoms (namely carcinoid syndrome). (3) Results: progression after salvage PRRT was observed in 29 of 32 patients with median PFS of 10.8 months (95% confidence interval (CI), 8.0\u201315.9 months). A higher LLS (hazard ratio (HR): 1.03; p = 0.002) and a higher De Ritis ratio (HR: 2.64; p = 0.047) were associated with shorter PFS after salvage PRRT in univariable Cox regression. PFS after initial PRRT was not associated with PFS following salvage PRRT. In multivariable Cox regression, only LLS remained a significant predictor. (4) Conclusions: the size of the largest lesion is easy to obtain and might help identify patients at risk of early disease progression after salvage PRRT. Validation is required.<\/jats:p>","DOI":"10.3390\/cancers14071768","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:33:03Z","timestamp":1648762383000},"page":"1768","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-9288","authenticated-orcid":false,"given":"Markus","family":"Galler","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2014Universit\u00e4t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-6532","authenticated-orcid":false,"given":"Julian M. M.","family":"Rogasch","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2014Universit\u00e4t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Charit\u00e9platz 1, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-8693","authenticated-orcid":false,"given":"Kai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2014Universit\u00e4t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Jann","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2014Universit\u00e4t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Plehm","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2014Universit\u00e4t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-1375","authenticated-orcid":false,"given":"Christoph","family":"Wetz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2014Universit\u00e4t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0657","authenticated-orcid":false,"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2014Universit\u00e4t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000369275","article-title":"Grading of neuroendocrine neoplasms: Mitoses and Ki-67 are both essential","volume":"100","author":"Groen","year":"2014","journal-title":"Neuroendocrinology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00423-011-0794-7","article-title":"The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant","volume":"396","author":"Modlin","year":"2011","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2010.07.002","article-title":"Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy","volume":"139","author":"Oberg","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: An analysis of the NETTER-1 study","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ruhwedel, T., Rogasch, J.M.M., Huang, K., Jann, H., Schatka, I., Furth, C., Amthauer, H., and Wetz, C. (2021). The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers, 13.","DOI":"10.3390\/cancers13040635"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MNM.0000000000001350","article-title":"Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis","volume":"42","author":"Kim","year":"2021","journal-title":"Nucl. Med. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rudisile, S., Gosewisch, A., Wenter, V., Unterrainer, M., Boning, G., Gildehaus, F.J., Fendler, W.P., Auernhammer, C.J., Spitzweg, C., and Bartenstein, P. (2019). Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): Dosimetry, toxicity, efficacy, and survival. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6000-y"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00259-013-2547-z","article-title":"Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours","volume":"41","author":"Sabet","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"Brabander","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20180041","DOI":"10.1259\/bjr.20180041","article-title":"Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: Efficacy and prognostic factors for response","volume":"91","author":"Vaughan","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00259-015-3105-7","article-title":"Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC","volume":"42","author":"Severi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00259-017-3652-1","article-title":"Safety of multiple repeated cycles of (177)Lu-octreotate in patients with recurrent neuroendocrine tumour","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2967\/jnumed.109.068957","article-title":"Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors","volume":"51","author":"Krenning","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_18","unstructured":"R Development Core Team (2020). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_19","first-page":"745742","article-title":"smoothHR: An R package for pointwise nonparametric estimation of hazard ratio curves of continuous predictors","volume":"2013","author":"Gude","year":"2013","journal-title":"Comput. Math. Methods Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Budczies, J., Klauschen, F., Sinn, B.V., Gyorffy, B., Schmitt, W.D., Darb-Esfahani, S., and Denkert, C. (2012). Cutoff Finder: A comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051862"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Strosberg, J., Leeuwenkamp, O., and Siddiqui, M.K. (2021). Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis (vol 93, 102141, 2021). Cancer Treat Rev., 97.","DOI":"10.1016\/j.ctrv.2021.102203"},{"key":"ref_22","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"Bardies","year":"1995","journal-title":"J. Nucl. Med."},{"key":"ref_23","first-page":"1841","article-title":"Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size","volume":"42","author":"Breeman","year":"2001","journal-title":"J. Nucl. Med."},{"key":"ref_24","first-page":"13S","article-title":"Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs","volume":"46","author":"Breeman","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-4827(02)00027-7","article-title":"Necrosis: A specific form of programmed cell death?","volume":"283","author":"Proskuryakov","year":"2003","journal-title":"Exp. Cell Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ejrad.2015.05.005","article-title":"Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade","volume":"84","author":"Takumi","year":"2015","journal-title":"Eur. J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4251\/wjgo.v12.i8.893","article-title":"Clinical and pathological characteristics and prognosis of 132 cases of rectal neuroendocrine tumors","volume":"12","author":"Yu","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4329\/wjr.v5.i6.241","article-title":"Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?","volume":"5","author":"Neperud","year":"2013","journal-title":"World J. Radiol."},{"key":"ref_29","first-page":"117","article-title":"The de ritis ratio: The test of time","volume":"34","author":"Botros","year":"2013","journal-title":"Clin. Biochem. Rev."},{"key":"ref_30","first-page":"817","article-title":"The past and present of serum aminotransferases and the future of liver injury biomarkers","volume":"15","author":"McGill","year":"2016","journal-title":"EXCLI J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0009-8981(89)90216-7","article-title":"Different patterns of leakage of cytosolic and mitochondrial enzymes","volume":"185","author":"Kamiike","year":"1989","journal-title":"Clin. Chim. Acta"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.15252\/embj.201696151","article-title":"Cancer cell metabolism: The essential role of the nonessential amino acid, glutamine","volume":"36","author":"Zhang","year":"2017","journal-title":"EMBO J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/bcr2154","article-title":"Targeting aspartate aminotransferase in breast cancer","volume":"10","author":"Thornburg","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yang, C.S., Stampouloglou, E., Kingston, N.M., Zhang, L., Monti, S., and Varelas, X. (2018). Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ\/YAP-activated cancer cells. EMBO Rep., 19.","DOI":"10.15252\/embr.201643577"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.4161\/cc.25307","article-title":"Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance","volume":"12","author":"Lyssiotis","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/j.clgc.2016.08.023","article-title":"De Ritis Ratio (AST\/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery","volume":"15","author":"Lee","year":"2017","journal-title":"Clin. Genitourin Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1758835919900872","DOI":"10.1177\/1758835919900872","article-title":"The AST\/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: Post hoc analysis of an Austrian multicenter, noninterventional study","volume":"12","author":"Riedl","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s11255-017-1618-7","article-title":"The significance of De Ritis (aspartate transaminase\/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients","volume":"49","author":"Wang","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1053\/j.gastro.2008.09.018","article-title":"Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease","volume":"135","author":"Goessling","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2147\/NDT.S139316","article-title":"De Ritis ratio (AST\/ALT) as an independent predictor of poor outcome in patients with acute ischemic stroke","volume":"13","author":"Gao","year":"2017","journal-title":"Neuropsychiatr Dis. Treat"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e3843","DOI":"10.1097\/MD.0000000000003843","article-title":"The AST\/ALT (De-Ritis) ratio: A novel marker for critical limb ischemia in peripheral arterial occlusive disease patients","volume":"95","author":"Rief","year":"2016","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/7\/1768\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:47:10Z","timestamp":1760136430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/7\/1768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["cancers14071768"],"URL":"https:\/\/doi.org\/10.3390\/cancers14071768","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}